Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function
Table 3
Cardiovascular risk factors and follow-up cardiac events.
Low cystatin C (≤ 0.90 mg/L, n = 211)
High cystatin C (> 0.90 mg/L, n = 211)
MetS (-), n = 160
MetS (+), n = 51
MetS (-), n = 128
MetS (+), n = 83
P value
CRP > 5 μg/mL, n (%)
55 (34.4)
28 (54.9)
103 (80.5)
76 (91.6)
<0.001
BNP > 100 pg/mL, n (%)
44 (27.5)
17 (33.3)
64 (50.0)
43 (51.8)
<0.001
Killip class > 1, n (%)
30 (18.8)
9 (17.6)
74 (57.8)
49 (59.0)
<0.001
Multivessel disease, n (%)
42 (26.3)
16 (31.4)
108 (84.4)
79 (95.2)
<0.001
GRACE score ≥ 89, n (%)
65 (40.6)
24 (47.1)
109 (85.2)
70 (84.3)
<0.001
SYNTAX score ≥ 23, n (%)
5 (3.1)
2 (3.9)
31 (24.2)
27 (32.5)
<0.001
MACEs, n (%)
13 (8.1)
7 (13.7)
30 (23.4)
26 (31.3)
<0.001
Cardiac death, n (%)
2 (1.3)
1 (2.0)
6 (4.7)
7 (8.4)
0.036
Non-fatal MI, n (%)
3 (1.9)
3 (5.9)
8 (6.3)
6 (7.2)
0.116
TVR, n (%)
4 (2.5)
3 (5.9)
9 (7.0)
8 (9.6)
0.086
Heart failure, n (%)
2 (1.3)
0 (0)
5 (3.9)
4 (4.8)
0.182
Non-fatal stroke, n (%)
2 (1.3)
0 (0)
2 (1.6)
1 (1.2)
1.000
Data are expressed as n (%). P value is from Chi-square test or Fisher exact test. Abbreviations. CRP: C-reaction protein; BNP: B-type natriuretic peptide; MACEs: major adverse cardiovascular events; MI: myocardial Infarction; TVR: target vessel revascularization; MetS: metabolic syndrome.
